Skip to main content
. 2021 Sep 6;11:696512. doi: 10.3389/fonc.2021.696512

Figure 2.

Figure 2

Sum of tumor shrinkage and best response per RECIST v1.1 (n = 11). Tumor shrinkage measured from baseline. One response-evaluable patient received first dose of nivolumab but had progressive disease before first tumor assessment and was excluded here. PD-L1, programmed death ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors.